Moleculin Biotech, Inc. (MBRX): Insider Trading, Congress Trades & Research | Tormere

MBRX

$9.27+30.77%download financials (.py)

Moleculin Biotech, Inc.

Market Cap

$6M

As of 2026-10-17

Sector

Health Care

Industry

Biotechnology

Beta (raw)

2.82

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Price / TTM revenue

P/B

0.5

Price / stockholders equity

EV/EBITDA

—

TTM

Price Chart

Loading…

Signals

Insider Velocity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

Analyst Consensus

Strong Buy

9 analysts

Velocity Score

25.65x

Avg Daily Buying (90d)

11,111 sh/day

Baseline Daily Buying

0.0 sh/day

Unique Buyers (90d)

3

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-08-03	2026-08-05	Foster Jonathan P.	Chief Financial Officer	Purchase	293.3K	—	—	305.7K	View
2026-08-03	2026-08-05	KLEMP WALTER V	Director & CEO and President	Purchase	533.3K	—	—	564.3K	View
2026-08-03	2026-08-05	PICKER DONALD H	Chief Science Officer	Purchase	173.3K	—	—	174.1K	View

Recent News

Moleculin Biotech (MBRX) Stock Price, News & Analysis

Stock Titan · 2026-10-25

Moleculin Biotech, Inc. Estimates – NASDAQ:MBRX

TradingView · 2026-10-23

Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial

Yahoo · 2026-10-20

Moleculin Biotech (MBRX) Announces 1-for-20 Reverse Stock Split Amid Market Selloff

GuruFocus · 2026-10-16

US Gap-Up and Gap-Down Stocks in the October 16, 2026 Session

ChartMill · 2026-10-16

Moleculin Announces Reverse Stock Split

Yahoo · 2026-10-16

Moleculin Biotech Announces 1-For-20 Reverse Stock Split, Effective October 20

Benzinga · 2026-10-16

Moleculin Biotech to Participate in Advances in Oncology Panel at the 2026 Maxim Growth Summit

Yahoo · 2026-10-07

Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout

Yahoo · 2026-09-29

Moleculin Biotech Completes Patient Enrollment In Part A Of Its Pivotal Phase 2/3 MIRACLE Study Of Annamycin In Combination With Cytarabine To Treat Adults With Relapsed Or Refractory Acute Myeloid Leukemia

Benzinga · 2026-09-29

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

Yahoo · 2026-09-28

Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR

Yahoo Finance · 2026-09-25

Moleculin Biotech Secures Mexican Patent Protecting Lung-Targeted Liposomal Annamycin Through 2040

Yahoo Finance · 2026-09-23

Moleculin to Showcase New Annamycin Data at AACR Conference on Pancreatic Cancer and Two European Scientific Meetings

Yahoo Finance · 2026-09-14

Moleculin Presentation from H.C. Wainwright Conference Now Available On-Demand

Yahoo Finance · 2026-09-11

Informational purposes only, not investment advice.